ArticleScience translational medicine2021
Down-regulation of A20 promotes immune escape of lung adenocarcinomas.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.5field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 39 citations in OpenAlex.
- A20 Inhibits IFN-γ Signaling in Hepatocellular Carcinoma Cells by Binding to STAT1, Compromising Anti-Tumor Immunity.Cancer science · 2026Article
- The ubiquitin-editing enzyme A20 (TNFAIP3): mechanisms of activation, biological function, diseases and therapeutic targets.Molecular biomedicine · 2026Review
- Article
- STAT1 accelerates cutaneous melanoma progression through TUBB4A expression regulation.Molecular medicine reports · 2026Article
- Article
- Pathological role of deubiquitinating enzymes in lung cancer: recent insights and advances.American journal of cancer research · 2026Review
- Negative regulators antagonizing antitumor innate immune pathways in lung cancer immune evasion.Frontiers in immunology · 2026Review
- Saliva from oral squamous cell carcinoma patients promotes tumor progression via Inflammation, stromal remodeling, and metabolic reprogramming in a mouse model.BMC oral health · 2025Article
- The Role of A20 in Cancer: Friend or Foe?Cells · 2025Review
- RadioFlow Cytometry Reveals That [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Lung cancer tumor immune microenvironment: analyzing immune escape mechanisms and exploring emerging therapeutic targets.Frontiers in immunology · 2025Review
- Dissecting the dual role of OTU family proteins in tumor progression and immune escape.Frontiers in immunology · 2025Review
- IFN-gamma in the tumor microenvironment: dual roles in cancer progression and therapy.EXCLI journal · 2025Review
- OTU deubiquitinases in cancer pathogenesis and precision therapy.American journal of cancer research · 2025Review
- Review
- Detection of neoplastic-immune hybrid cells with metastatic properties in uveal melanoma.Biomarker research · 2024Article
- Advances of E3 ligases in lung cancer.Biochemistry and biophysics reports · 2024Review
- Viperin inhibits interferon-γ production to promote Mycobacterium tuberculosis survival by disrupting TBK1-IKKε-IRF3-axis and JAK-STAT signaling.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Article
- LINC01686 affects LPS-induced cytokine expression via the miR-18a-5p/A20/STAT1 axis in THP-1 cells.Immunity, inflammation and disease · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 7 institutions in 3 countries.
Kristina BreiteneckerInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0002-5334-6377
Monika HomolyaInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0002-0735-7710
Andreea C LucaInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0003-1519-5464
Veronika LangInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0001-9844-9153
Christoph TrenkInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0002-9754-181X
Georg PetrocziInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0003-3069-6013
Julian MohrherrInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
Jaqueline HorvathInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0002-2031-5515
Stefan MoritschInstitute of Cancer Research, Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0002-1849-1616
Lisa HaasResearch Institute of Molecular Pathology, Vienna Biocenter, AT-1030 Vienna, Austria.
Margarita KurnaevaInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0002-9769-5982
Robert EferlInstitute of Cancer Research, Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0002-6074-7144
Dagmar StoiberInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0002-8824-0767
Richard MorigglInstitute of Animal Breeding and Genetics, University of Veterinary Medicine, AT-1210 Vienna, Austria.ORCID 0000-0003-0918-9463
Martin BilbanDepartment of Laboratory Medicine, Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0001-7043-7142
Anna C ObenaufResearch Institute of Molecular Pathology, Vienna Biocenter, AT-1030 Vienna, Austria.ORCID 0000-0002-9556-5914
Christiane FerranDivision of Vascular and Endovascular Surgery and the Center for Vascular Biology Research, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-3379-7998
Balazs DomeDivision of Thoracic Surgery, Department of Surgery, and Comprehensive Cancer Center (CCC), Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0001-8799-8624
Viktoria LaszloDivision of Thoracic Surgery, Department of Surgery, and Comprehensive Cancer Center (CCC), Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0002-6567-3965
Balázs GyőrffyMTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, and 2nd Department of Pediatrics, Semmelweis University, HU-1117 Budapest, Hungary.
Katalin Dezso1st Department of Pathology and Experimental Cancer Research, Semmelweis University, HU-1085 Budapest, Hungary.ORCID 0000-0002-4856-0483
Judit Moldvay1st Department of Pulmonology, National Korányi Institute of Pulmonology, HU-1121 Budapest, Hungary.ORCID 0000-0001-9425-1748
Emilio CasanovaInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0001-7992-5361
Herwig P MollInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria. herwig.moll@meduniwien.ac.at.ORCID 0000-0001-6438-9068
Medical University of Vienna · ATComprehensive Cancer Center Vienna · ATSemmelweis University · HUResearch Institute of Molecular Pathology · ATBeth Israel Deaconess Medical Center · USKarl Landsteiner University of Health Sciences · ATUniversity of Veterinary Medicine Vienna · AT
Funding
Austrian Science Fund FWF DOC 59Austrian Science Fund FWF F 4707Austrian Science Fund FWF F 6105Austrian Science Fund FWF I 3522Austrian Science Fund FWF I 3977Austrian Science Fund FWF I 4157Austrian Science Fund FWF I 4677Austrian Science Fund FWF P 25599Austrian Science Fund FWF P 32900Austrian Science Fund FWF P 33430
Abstract
Inflammation is a well-known driver of lung tumorigenesis. One strategy by which tumor cells escape tight homeostatic control is by decreasing the expression of the potent anti-inflammatory protein tumor necrosis factor alpha-induced protein 3 (TNFAIP3), also known as A20. We observed that tumor cell intrinsic loss of A20 markedly enhanced lung tumorigenesis and was associated with reduced CD8
Indexed as
Adenocarcinoma of LungLung NeoplasmsAnimalsB7-H1 AntigenDown-RegulationHumansInterferon-gammaMiceSignal TransductionTumor Necrosis Factor alpha-Induced Protein 3B7-H1 AntigenInterferon-gammaTNFAIP3 protein, humanTumor Necrosis Factor alpha-Induced Protein 3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.